Merck's Welireg meets co-primary endpoint in kidney cancer PhIII; Noveome raises half of planned $40M VC round

Merck said Friday morning that its HIF-2α inhibitorHIF-2α inhibitor Welireg met the co-primary endpoint of progression-free survival in a Phase III trial for patients with advanced forms of renal cell carcinoma, but it did not meet the other co-primary endpoint of overall survival.

The topline data come from a head-to-head Phase III trial with everolimus, also known as Novartis’ Afinitor, testing Welireg in pre-treated patients with advanced forms of renal cell carcinoma.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。